Analysis of risk factors for recurrence in cervical cancer patients after fertility-sparing treatment: The FERTISS retrospective multicenter study.

Archive ouverte

Sláma, J. | Runnebaum, I. B. | Scambia, G. | Angeles, M. A. | Bahrehmand, K. | Kommoss, S. | Fagotti, A. | Narducci, Fabrice | Matylevich, O. | Holly, J. | Martinelli, F. | Koual, M. | Kopetskyi, V. | El-Balat, A. | Corrado, G. | Căpîlna, M. E. | Schröder, W. | Novàk, Z. | Shushkevich, A. | Fricová, L. | Cibula, D.

Edité par CCSD ; Elsevier -

International audience. BackgroundFertility-sparing treatment in patients with cervical cancer should, in principle, follow identical algorithms to that in patients without future reproductive plans. In recent years, a trend toward nonradical procedures, such as conization or simple trachelectomy, has become apparent in medical literature, because of their associations with better pregnancy outcomes. However, the published reports included small numbers of patients and heterogenous treatment strategies to ascertain the safety of such approaches.ObjectiveThis study aimed to collect multi-institutional data regarding the oncological outcomes after fertility-sparing treatment in patients with cervical cancer and to identify prognostic risk factors, including the influence of the radicality of individual cervical procedures.Study DesignPatients aged 18 to 40 years with International Federation of Gynecology and Obstetrics 2018 stage IA1 with positive lymphovascular space invasion or ≥IA2 cervical cancer who underwent any type of fertility-sparing procedure were eligible for this retrospective observational study, regardless of their histotype, tumor grade, and history of neoadjuvant chemotherapy. Associations between disease- and treatment-related characteristics with the risk of recurrence were analyzed.ResultsA total of 733 patients from 44 institutions across 13 countries were included in this study. Almost half of the patients had stage IB1 cervical cancer (49%), and two-thirds of patients were nulliparous (66%). After a median follow-up of 72 months, 51 patients (7%) experienced recurrence, of whom 19 (2.6%) died because of the disease. The most common sites of recurrence were the cervix (53%) and pelvic nodes (22%). The risk of recurrence was 3 times higher in patients with tumors >2 cm in size than in patients with smaller tumors, irrespective of the treatment radicality (19.4% vs 5.7%; hazard ratio, 2.982; 95% confidence interval, 1.383–6.431; P=.005). The recurrence risk in patients with tumors ≤2 cm in size did not differ between patients who underwent radical trachelectomy and patients who underwent nonradical (conization and simple trachelectomy) cervical procedures (P=.957), regardless of tumor size subcategory (<1 or 1–2 cm) or lymphovascular space invasion.ConclusionNonradical fertility-sparing cervical procedures were not associated with an increased risk of recurrence compared with radical procedures in patients with tumors ≤2 cm in size in this large, multicenter retrospective study. The risk of recurrence after any type of fertility-sparing procedure was significantly greater in patients with tumors >2 cm in size.

Consulter en ligne

Suggestions

Du même auteur

SUCCOR cone study: conization before radical hysterectomy.

Archive ouverte | Chacon, E. | CCSD

International audience. Objective To evaluate disease-free survival of cervical conization prior to radical hysterectomy in patients with stage IB1 cervical cancer (International Federation of Gynecology and Obstetr...

Radical hysterectomy in early cervical cancer in Europe: characteristics, outcomes and evaluation of ESGO quality indicators.

Archive ouverte | Boria, F. | CCSD

International audience. Introduction Comprehensive updated information on cervical cancer surgical treatment in Europe is scarce.Objective To evaluate baseline characteristics of women with early cervical cancer and...

ESGO–ESMO–ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease

Archive ouverte | Ledermann, J.A. | CCSD

International audience. The European Society of Gynaecological Oncology, the European Society for Medical Oncology (ESMO) and the European Society of Pathology held a consensus conference (CC) on ovarian cancer on 1...

Chargement des enrichissements...